Marg McGee
Major grant funding to progress lipid-based ...
Major grant funding to progress lipid-based therapies to treat prostate cancer
Marg McGee
Inaugural FCMHW Early Career Research Fellow at ...
Inaugural FCMHW Early Career Research Fellow at Flinders University - Jasmine Petersen
Marg McGee
Congratulations 2022 Honours Scholarship ...

Congratulations to the Centre’s 2022 Honours students on their scholarship awards and we wish them all the best for their research and training

Congratulations 2022 Honours Scholarship awardees
Publications, media release, Feature publication
Kelsey Long
Validation of a short form Male Depression Risk ...

Validation of the Male Depression Risk Scale short form in a cross-sectional study of Australian men. Herreen D, Rice S, Zajac I. Brief assessment of male depression in clinical care:BMJ Open. 2022 Mar 28;12(3):e053650. doi: 10.1136/bmjopen-2021-053650.

Contact: Dr Ian Zajac

Validation of a short form Male Depression Risk Scale
Kelsey Long
The Women of the FCMHW - International Women's ...

To celebrate International Women’s Day, the Centre is highlighting some of the fantastic women of men’s health that have been supported by the Centre and are achieving great work in the field. FCMHW encourages and commends the involvement of women in men’s health and hopes to further support it in the future.

The Women of the FCMHW - International Women's Day

drug target

World first study to catalog all lipid species in prostate cancer - informing future treatment strategies

World first study to catalog all lipid species in prostate cancer - informing future treatment strategies

Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition.
Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, Mutuku SM, Spotbeen X, Bagadi M, Waltregny D, Moldovan M, Dehairs J, Vanderhoydonc F, Bloch K, Das R, Stahl J, Kench JG, Gevaert T, Derua R, Waelkens E, Nassar ZD, Selth LA, Trim PJ, Snel MF, Lynn DJ, Tilley WD, Horvath LG, Centenera MM, Swinnen JV.
Cancer Res. 2021 Aug 6:canres.3863.2020. doi: 10.1158/0008-5472.CAN-20-3863. PMID: 34362796
Contact: Lisa Butler

ELOVL5: Inching closer to a new therapeutic strategy for prostate cancer

ELOVL5: Inching closer to a new therapeutic strategy for prostate cancer

ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer
Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zininos I, Dehairs J, Burvenich IJG, Zadra G, Chetta P, Bango C, Evergren E, Ryan NK, Gillis JL, Mah CY, Tieu T, Hanson AR, Carelli R, Bloch K, Panagopoulos V, Waelkens E, Derua R, Williams ED, Evdokioou A, Cifuentes-Rius A, Voelcker NH, Mills IG, Tilley WD, Scott AM, Loda M, Selth LA, Swinnen JV, Butler LM. Cancer Res. 2021 Feb 5:canres.2511.2020. doi: 10.1158/0008-5472.CAN-20-2511.
Contact: Maggie Centenera

miR-194: a potential therapeutic target to prevent drug resistant prostate cancer

miR-194: a potential therapeutic target to prevent drug resistant prostate cancer

Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.
Fernandes RC, Toubia J, Townley S, Hanson AR, Dredge BK, Pillman KA, Bert AG, Winter JM, Iggo R, Das R, Obinata D; MURAL investigators, Sandhu S, Risbridger GP, Taylor RA, Lawrence MG, Butler LM, Zoubeidi A, Gregory PA, Tilley WD, Hickey TE, Goodall GJ, Selth LA. Cell Rep. 2021 Jan 5;34(1):108585. doi: 10.1016/j.celrep.2020.108585.
Contact: Luke Selth